Could microdosing GLP-1 drugs boost longevity?
Key claim: Scientific American examines the emerging trend and speculative rationale behind microdosing GLP-1 receptor agonists to promote longevity while avoiding full-dose gastrointestinal side effects and excessive weight loss.
Abstract
News coverage by Scientific American: “Could microdosing GLP-1 drugs boost longevity?”. Headline and link only — this finding reports press coverage of a government action, not the primary record.
Why this matters
Scientific American’s coverage brings mainstream attention to a reported biohacking and off-label clinical trend: using smaller GLP-1 doses for longevity while hoping to limit unwanted effects [anecdotal-biohack]. The longevity rationale remains speculative [mechanism-plausible]; this finding supplies no clinical outcome data showing that microdosing delivers longevity benefits or the claimed safety advantages, so the new signal concerns trend visibility rather than demonstrated benefit.